Comparative Study of Pemetrexed or Gemcitabine Combined with Cisplatin for Advanced Lung Adenocarcinoma

Objective To explore the efficacy and toxicities of pemetrexed or gemcitabine combined with cisplatin in the first-line treatment of advanced lung adenocarcinoma. Methods 60 cases of stage Ⅲb and stage Ⅳ lung adenocarcinoma were randomly divided into two groups. The experimental group( PP group) 30 cases,with pemetrexed 500 mg / m2intravenous infusion of D1 + cisplatin 25 mg / m2intravenous infusion of D1-3,every 3 weeks for 1 cycle of chemotherapy. The control group( GP group) 30 cases,with gemcitabine intravenous infusion of 1 000mg / m2D1 + and cisplatin 25 mg / m2intravenous infusion of D1-3,every 3 weeks for 1 cycle of chemotherapy. Curative effects and adverse reactions were evaluated after 2 cycles. Results The efficiency of experimental group and control group were 30. 0% and 26. 7%,and disease control rates were 66. 7% and 70. 0%. There was no significant difference( P 0. 05). Adverse reaction showed that grade Ⅲ-Ⅳ leucopenia occurrence rates of the experimental group and the control group were 13. 3%( 4 /30) and 40. 0%( 12 /30). The difference was statistically significant( P 0. 05). Grade Ⅲ-Ⅳ anemia incidence rates were 3. 3%( 1 /30),and 6. 7%( 2 /30),there was no significant difference( P 0. 05); Grade Ⅲ-Ⅳ thrombocytopenia occurrence rates were 6. 7%( 2/30),36. 7%( 11/30). The difference was statistically significant( P 0. 05). There was no statistical difference in liver and kidney function damage,nausea and vomiting; the incidence of alopecia in experimental group and control group were 10. 0%( 3 /30),and 33. 3%( 10 /30),the difference was statistical significant( P 0. 05). Conclusion Pemetrexed combined with cisplatin is effective for advanced lung adenocarcinoma with tolerable side effects.